Structure-Guided Design and Biophysical Characterization of Novel Anti-HIV Reagents by Jiang, Siduo (Stone)
 i 
STRUCTURE-GUIDED DESIGN AND BIOPHYSICAL CHARACTERIZATION 
OF NOVEL ANTI-HIV REAGENTS 
 
 
Thesis by 
Siduo Jiang 
 
In Partial Fulfillment of the Requirements for the 
degree of 
Biology 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
2014 
 
 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 2014 
Siduo Jiang 
All Rights Reserved
iii 
 
ACKNOWLEDGEMENTS 
Firstly, I would like to especially thank my thesis advisor Pamela for the amazing four years 
and two summers spent in her lab. Pamela gave the first seminar that I ever attended at 
Caltech on engineering antibody architectures. From that lecture, I discovered a new 
passion for protein structure and design, which under your close mentorship has evolved 
into an exciting new career path. I am greatly thankful for our conversations which are 
always educational for me, and especially the chance to prepare two theses and a draft of 
a manuscript under your guidance. The opportunity to join your lab and be your student has 
been one of highlights of my college career. 
As the person that first interviewed me, I would especially like to thank Anthony for getting 
me even more excited about the lab. You were always there to keep me on track and 
instrumental in focusing my ideas into something worthwhile and tangible. It was great when 
we were initially making the gp120 mutants: my first constructs where one or two mutations 
actually made a huge difference in binding. Thank you again for being a phenomenal mentor 
and welcoming me to the lab. 
And to Rachel, who has been an inspiration from the very start, from showing me how to 
clone, to enlightening my mind with brilliant ideas, and teaching me immunology. I could not 
thank you enough for being such an amazing mentor and friend. I always feel like I am 
constantly bugging you, but really, I would not be anywhere without all of your help and 
advice. It was always a blast working with you and hanging out both in and out of lab; I hope 
you will return to NYC before I leave there! 
Of course, even though I have worked with Stuart for the least amount of time, your strict 
work style has rubbed off on me in the best way possible. I can no longer write more than 3 
lines of code without annotating, and I cannot design primers without quadruple checking 
the sequence. Your knowledge of protein design is really inspiring, and I learned a 
tremendous amount from you and your excellent, constant feedback. Also, I hope I have not 
driven you crazy with sometimes trying to re-invent the wheel. 
 
iv 
 
Finally, I am greatly thankful to all lab members for always lending a hand and making me 
feel welcome, even though I was the youngest and least experienced for the longest time. 
 
 
  
 
v 
 
ABSTRACT 
Despite over 30 years of effort, an HIV-1 vaccine that elicits protective antibodies 
still does not exist. Recent clinical studies have identified that during natural infection 
about 20% of the population is capable of mounting a potent and protective antibody 
response. Closer inspection of these individuals reveal that a subset of these 
antibodies, recently termed potent VRC01-like (PVL), derive exclusively from a 
single human germline heavy chain gene. Induced clonal expansion of the B cell 
encoding this gene is the first step through which PVL antibodies may be elicited. 
Unfortunately, naturally occurring HIV gp120s fail to bind to this germline, and as a 
result cannot be used as the initial prime for a vaccine regimen. We have determined 
the crystal structure of an important germline antibody that is a promising target for 
vaccine design efforts, and have set out to engineer a more likely candidate using 
computationally-guided rational design.  
  In addition to prevention efforts on the side of vaccine design, recently 
characterized broadly neutralizing anti-HIV antibodies have excellent potential for 
use in gene therapy and passive immunotherapy. The separation distance between 
functional Fabs on an antibody is important due to the sparse distribution of envelop 
spikes on HIV compared to other viruses. We set out to build and characterize novel 
antibody architectures by incorporating structured linkers into the hinge region of an 
anti-HIV antibody b12. The goal was to observe whether these linkers increased the 
arm-span of the IgG dimer. When incorporated, flexible Gly4Ser repeats did not 
result in detectable extensions of the IgG antigen binding domains, by contrast to 
linkers including more rigid domains such as β2-microglobulin, Zn-α2-glycoprotein, 
and tetratricopeptide repeats (TPRs). This study adds an additional set of linkers 
with varying lengths and rigidities to the available linker repertoire, which may be 
useful for the modification and construction of antibodies and other fusion proteins.   
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Chapter I 
 
Structure-guided Engineering of Novel Vaccine Candidates 
Against HIV 
 
In this study we report the crystallography of a germline anti-HIV antibody and preliminary 
design efforts for creating a novel vaccine candidate against HIV.  
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Background 
The HIV pandemic continues to burden more than 30 million individuals worldwide with 
nearly 70% of all cases presenting in the developing countries of Sub-Saharan Africa1. 
While antiretroviral therapy (ART) has proven to be highly effective in controlling disease 
in much of the Western world, these African countries lack both the economic and clinical 
resources necessary to successfully deliver drugs to all patients in need. This is especially 
evident in South Africa, where HIV prevalence is as high as 50% in the regions of Kwa-
Zulu Natal, with an overwhelming 21% of the population afflicted with severe AIDS. In 
spite of these statistics, only about 25% of the total positive population is receiving clinical 
attention.  
  Today, it is becoming evident that these expensive and unpleasant anti-retrovirals that 
provide at best transient protection is not a permanent solution2. Much work therefore has 
been devoted to the effort of developing a vaccine. To date, six HIV-1 vaccines have gone 
through Phase IIb/III efficacy trials and all have failed to significantly reduce viral 
transmission.  
 
Table 1 summarizes these findings and compares the mechanism by which each candidate 
attempted to elicit immunity. Despite the importance of cell-mediated responses in 
preventing severe disease3, it is considered only as a second line of defense after the 
antibody response. This is due to the fact that cell-mediated immunity can suppress viral 
production in already infected cells, but is incapable of preventing viral transmission and 
therefore new infections4. As a result, a potent antibody response will likely be a critical 
component of an effective vaccine.  
Table 1. Completed HIV-1 vaccine efficacy trials 
Trial name Vaccine candidate Elicited Immunity Reduction in new 
infections 
Year 
completed 
VAX0045 Single gp120 Antibody response No reduction 2005 
VAX0036 Bivalent gp120 Antibody response No reduction 2006 
HVTN5027 Adenovirus containing  HIV-1 gag/pol/nef 
genes 
Cellular response No reduction 2007 
RV1449 VAX003 plus canarypox virus containing 
HIV-1 env/gag/pol genes 
Antibody and cellular 
response 
31.2% efficacy  2009 
HVTN5039 HVTN502; done in different country Cellular response No reduction 2011 
HVTN50510 Adenovirus containing  HIV-1 
gag/pol/nef/env (gp120) genes 
Antibody and cellular 
response 
No reduction 2013 
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Currently, many problems exist with eliciting an effective antibody response against 
HIV3,11,12. The most notable is the rapid mutational rate of the HIV Env gene encoding 
surface antigen gp120, which mediates viral entry, leading to massive diversification of the 
circulating viral strains within a single infected individual. Glycan shields and 
conformational masking of critical epitopes can also guard gp120 against immune 
recognition. No natural antigen to date (such as that used in VAX003/004) has been able 
to elicit broadly neutralizing antibodies (bNAbs) capable for tackling these diverse and 
structurally-protected strains3. The responses from past clinical trials have been weak 
overall13, represented by the development strain-specific or non-neutralizing antibodies14. 
It is becoming evident therefore that a more targeted approach using rational design is 
necessary for generating an antigen suitable for use in an antibody-based vaccine. 
 In the past decade, clinical studies have identified that approximately 20% of HIV-1 
infected individuals are capable of producing bNAbs, but the natural process takes about 2 
years to be successful15. These antibodies, when delivered passively, are protective 
against infection in animal models. One of the most potent and broad class of these 
antibodies is the one which targets the natural gp120 ligand-binding site (the CD4-binding 
site)16, and a subclass of these CD4-binding site antibodies, recently termed potent 
VRC01-like (PVL)17, are a particularly promising class for vaccine design.  
 At a clinical scale, these PVL antibodies have been isolated independently from at least 6 
individuals10, which suggests that a broader population can develop this response. In 
addition, PVL heavy chains derive exclusively from the B cell germline IgVH VH1-2*02, and 
their light chains from three B cell germline IgVKs. This identification yields a promising 
starting point for vaccine design. As background, the process of antibody development 
begins with the successful coupling of a VJ-recombined18 germline heavy chain gene with 
a VJ-recombined germline light chain gene forming the germline B cell receptor (receptor 
is a membrane-bound version of secreted antibody). Upon antigen-binding to this receptor, 
the germline B cell is activated and undergoes clonal expansion followed by somatic 
hypermutation19, which diversifies the B cell receptor repertoire through genetic mutations. 
Positive selection for stronger antigen binders then takes place, thereby improving the 
average affinity of the B cell repertoire against the antigen. This process repeats a many 
times in the case of HIV, forcing the B cell receptor to evolve through several intermediate 
states before maturing into a potent broadly-neutralizing form. 
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 Since all PVL antibodies originally derive from the same germline IgVH, an effective 
vaccine would first induce activation and clonal expansion of that particular germline gene 
by utilizing a gp120 (antigen) that can strongly bind to that germline B cell receptor. 
Secondly, gp120s acting as booster shots should be administered in order to guide the 
process of somatic hypermutation. This would require antigens that bind to intermediates 
of the evolutionary pathway in order to put a selective advantage on B cells evolving in the 
correct direction. Since it is difficult to know with certainty the precise pathway of evolution, 
this task may be challenging. However, recent studies suggest that such a mechanism 
can be derived for specific cases with access to long-term patient data10,20,21. Furthermore, 
designed gp120s should all mimic the binding interface between natural gp120s and PVL 
antibodies. This would bias selection for intermediate antibodies preserving PVL structural 
features. If this can be achieved, there will be a better chance that the final product of 
these antibodies will be broadly neutralizing as the case with PVLs. 
 
Crystallography of 3BNC60 germline   
Presently, no natural gp120 reported in the literature appreciably binds to the VH1-2*02 
heavy chain coupled to any of its three germline light chain genes. A recently engineered 
gp120, named eOD-GT622, showed high nanomolar affinity for binding to the VH1-2*02 
heavy chain coupled to the germline light chain precursor (IgKV3-20*01) of 3 potent PVLs, 
one of which was  VRC0110,17.  When multimerized onto nanoparticles, eOD-GT6 
demonstrated moderate levels of B cell activation of the predicted germline in vitro, 
suggesting that this engineering method may be general for targeted activation of any 
desired germline receptor.  
 One major caveat with eOD-GT6 however is that the gp120 does not bind VH1-2*02 
coupled to the germline light chain precursor of the PVL 3BNC60 (IgKV1-33*01), which 
also represents the precursor to 26 other PVLs17. This larger repertoire suggests that this 
precursor may be able to evolve potent antibodies using multiple pathways. Antibodies 
evolved from this germline also typically have fewer insertions in the CDRH3 and CDRL3 
loops, likely indicating that they are faster to develop and easier to elicit.  
  In order to identify the bases for the lack of binding between the 3BNC60 germline and 
eOT-GT6, we determined the crystal structure of full 3BNC60 germline to 1.9Å resolution. 
Proteins for the construct were purified and concentrated down to 15mg/mL, and screened 
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using Crystal Screen, Index and PegRX, all from Hampton research. Phasing was 
performing by molecular replacement on a previous structure of the 3BNC60 germline, 
which lacked a critical “DISNY” insertion in the CDRL1.   
  As a result of this structure, we propose that a reason for the lack of binding between 
3BNC60 germline and eOD-GT6 may be attributed to an extended CDRL1 loop in the light 
chain of the 3BNC60 precursor (unpublished), which sterically precludes binding in an 
aligned structure (Figure 1). This loop may also inhibit other VRC01 germline binders such 
as engineered 426c23. In addition, eOT-GT6 contains only the outer domain of gp120, 
which removes important contacts of the inner domain and the bridging sheets responsible 
for improved potency of PVLs24. In the mature PVL NIH45-46 for example, increased 
contacts with the bridging sheets and inner domain as measured by buried surface area 
constitutes a large portion of the interactions. Since eOD-GT6 does not encode a selective 
advantage for developing inner domain and bridging sheet contacts, these features would 
be neutral in the antibody developmental process. Figure 1 summarizes these points 
through comparison of the germline antibodies in complex with eOD-GT6 and a wildtype 
gp120, 93TH057.  
 
 
 
 
 
Fig. 1. Structural features of eOD-GT6 
and 3BNC60 germline antibody. (A) A 
look at CDRL1 contacts. Currently, no 
engineered gp120 binds to the 3BNC60 
germline. One possible reason is that the 
CDRL1 loop of 3BNC60 germline (dark 
blue) is more extended compared to that 
of VRC01 germline (light blue), which 
sterically precludes binding by clashing 
with loop residues (R81 on eOD-GT6 in 
green) on the gp120. Clashes are 
indicated in red. The CDRL1 of VRC01 
germline makes a favorable hydrogen 
bond with the same Arg. (B) Alignment of 
3BNC60 germline onto a crystal structure 
of eOD-GT6 in complex with VRC01 
germline. eOD-GT6 does not have the 
bridging sheets (pink) or an inner domain 
(white), which in wildtype gp120 make 
significant contacts to increase the 
potency of mature PVLs. Such 
interactions should be engineered in 
future vaccine candidates.  
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Rational design of a 3BNC60 germline activator  
In this project, I designed and tested a series of gp120s with the goal of improving their 
binding to the 3BNC60 germline (derived from VH1-2*02 and IgKV1-33*01). The project 
utilized two primary tools: 1) computational design using the program Rosetta25, 2) high-
throughput biochemical techniques for validating and evolving potential binders.  
  We began by reconstructing the V5 loop which was not resolved in the original 
unliganded crystal structure of the entire core construct. This was done by manually 
inserting the residues in PyMOL, followed by a loop closure and refinement protocol 
implemented in Rosetta1. The refined NCSYU2 was then superimposed onto the crystal 
structure of eOD-GT6 (PDB: 4JPK)2 replacing the eOD portion (engineered outer domain 
of NCS93TH057) of the co-crystal forming the VRC01GL+NSCYU2. This entire structure 
was then subjected to a high resolution refinement protocol in Rosetta3 in order to 
generate an energetically stable complex as the starting point for design. The RMSD of 
the entire refined structure was within 0.5Å of the original docked VRC01GL+NCSYU2. 
Though eventually we wish to work with variously starting gp120 cores (including 
NCSYU2) and 3BNC60GL, this structure was easy enough to obtain as a test structure for 
generating the appropriate downstream scripts needed for operation on the final 
complexes.  
  Before re-designing the complex for greater stabilization, we needed to first define the 
residues to be subjected to multiple rounds of mutations and minimization. This was done 
using a PyMOL script which identifies the interface residues of the gp120 with either the 
HC or LC of the germline Ab (interface defined as residues of the gp120 with atoms which 
are within 10Å of an atom of either the HC or LC). These residues were identified, and a 
script which exports these residues in a Rosetta executable “resfile” was generated. The 
“resfile” stipulates that the defined interface residues may be mutated to any other residue 
(or remain unmutated) except cysteine. The script for this entire process is reliably and 
quickly applied to any starting structure.  
  The first step to design in Rosetta is to generate a task manager that simultaneously 
couples side-chain mutagenesis with rotamer re-packing post mutagenesis. The function 
used is named “PackResidueMover,” which we manipulated to read instructions of the 
“resfile.” The key to design is the “score function” of the protein complex, which accounts 
for biophysical energy terms such as the net van der Waals forces, hydrogen bonding and 
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solvation energy as well as statistical terms such as Ramachandran propensities. The 
score function calculates the overall energy of a complex depending on the weights of 
these parameters specified in the score function object; for example, a complex with 
several potential residue clashes would score a much higher global energy if the net van 
der Waals repulsive term is increased in the score function.  
  A “standard” set of parameters for the score function was defined in one of the first 
successful applications of Rosetta4 and became the basis for initial cycles of scripting 
testing and optimization. In addition to the design (mutagenesis) and repacking steps, we 
incorporated a series refinement movers which, after each repacking, makes slight 
adjustments to backbone torsion angles of the design residues in order to minimize 
energy. These movers accomplish this task by seeking out a steepest decent path toward 
a local minimum and accepts changes based off of the Metropolis Monte Carlo criterion5. 
Because of this, the global minimum may not always be achieved, but this may be 
accomplished with the high resolution refinement protocol previously used to refine the 
docked (a single application of this protocol takes over ~6 hours to run on the fastest lab 
machine so it is only used sparingly).  
  Eventually, we were able to generate a script which iterates over many cycles of design 
and repacking as opposed to a single round. Such a strategy suggests that there may be 
a more sensible approach to defining the score function used to evaluate each step of the 
design. A gradient-based score function was generated based off of the following logic. 
First, a decreased van der Waals repulsive terms was used while an increased attractive 
term was used so that the very initial refinement steps do not completely relax and “blow 
up” the structure. In other words, favorable interactions may be established initially without 
the worry that simultaneous generation of clashes prevents these favorable interactions to 
be accepted. This process is then reversed for later steps where after defining favorable 
interactions, the program attempts to correct unfavorable clashes. Statistical terms also 
follow a gradient path from having a low weight initially to a large weight in the later steps.   
This allows for sampling of residues at positions not generally employed by nature, which 
may be beneficial. The entire design, repacking, minimize procedure is interspaced with 
high resolution refinement, and acceptance of each intermediate structure is based off of 
Metropolis criterion. In order to gain a better understanding of the evolution of the gp120, 
the script commands that each generated structure, regardless of whether it is accepted, 
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be outputted as a PDB file. Lots of debugging and many overnights rounds of script testing 
took place with this entire protocol but a full script is ready to use for design and 
refinement of any starting structure. 
  One issue we have come across is that glycine interface residues, regardless of the 
number of iterations, are not subjected to mutations by the program. This may be that 
some residues are an absolute requirement at certain positions, but may also be that 
flexibility of these residues confuses the program by trapping the structure at a local 
minimum, and that the steps undertaken during each Monte Carlo design procedure is not 
large enough to escape this minimum. As a result, we are currently testing the potential of 
manually mutating all glycine residues to alanine initially, and increasing Ramachandran 
propensity weight term in the score function to ensure that positions which strictly require 
glycine readily mutate back.  
 For our designs, Rosetta was used to narrow the search space of possible gp120s by 
computationally optimizing the germline-antibody interface. The basic computational 
procedure started with the recently solved crystal structure of the 3BNC60 germline as 
shown in Figure 1 docked to a wildtype gp120. This complex was modeled using an 
alignment of the germline antibody to crystal structure of a mature antibody-gp120 
complex. An ensemble of such starting complexes was generated using rigid-body 
perturbations in Rosetta in order to represent some of the possible accessible states of an 
unstable starting complex. For each modeled complex, the residues which lie in close 
proximity to the antibody-gp120 interface was identified based on the residue’s buried 
surface area. From this analysis, Rosetta identified 28 residues on which to perform 
design calculations. Rosetta proceeded to randomly mutate these residues one at a time 
while optimizing rotomer conformation using fixed-backbone design. Each round of 
mutation was coupled with a backrub mover which allows the protein backbone to make 
adjustments. The energy of the designed complex was calculated using supplied values 
as well as potential functions internal to Rosetta, and each mutation is accepted or 
rejected based on the Metropolis criterion. For each residue, about a thousand mutations 
and rotomer optimizations were attempted. The design then proceeded through each 
residue and the energy for the final complex was generated. In order to allow multiple 
design trajectories, each initial perturbed complex was cycled through the design 
procedure several times to generate greater diversity.   
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 In order to supply Rosetta with desirable parameters for energy calculations, guidelines 
from past structural studies was employed. Characterizations of PVL antibodies, including 
3BNC60, have identified several exposed signature residues preserved across all PVLs 
that are critical residues for gp120 binding and HIV neutralization17. These residues mostly 
form hydrogen bonds near and around the CD4-binding site of the gp120. In order to 
mimic natural binding, these interactions need to be built and maintained in the design 
procedure. This was one of computational screening criteria used to identify desirable final 
structures.  
 At the end of the design procedure, the primary set of information that can be extracted 
was the preferred amino acid usage, or type of amino acid, at each of the designed 
interface positions. This includes critical residues for PVL contact, as well as other 
residues which potentially favor packing or build hydrophobic interactions. This was 
analyzed using a home-written script that identifies correlations of preferred amino acid 
usage at the designed positions.  
  Figure 2 presents the calculated amino acid preference at each of the designed 
positions. Some positions are highly consistent in amino acid usage; for example residues 
458 and 459 are preserved at Gly due to Ramachandran constraints at that position. Other 
positions are highly variable with a variety of hydrophobic, polar or charged residues. 
 
Figure 2. Preferred amino acid usage at Rosetta designed positions using fixed-backbone 
design. 
 
  With this information, libraries of randomized gp120s containing all possible combinations 
of these preferred amino acids was generated using degenerate primer Gibson cloning27. 
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Table 2 presents all of the potential mutations each position could become in this artificial 
library. The greatest diversity was generated in the CDR3 region of the antibody, which 
correspond to residues 455-463. Residues 458 and 459 were Gly residues with 
constrained torsion angles, which were identified by Rosetta to be necessary to maintain. 
 
Table 2. Potential mutations in engineered gp120 library following guideline from Rosetta 
calculations. 
Position Original amino 
acid 
Potential amino acids in engineered gp120 library 
275 Glu Glu, Met, Leu, Trp, Gln 
276 Asn Asn, Met, Thr, Asp 
278 Thr Thr, Met, Trp 
279 Asn Asn, Asp 
280 Asn Asn, Pro, Ala 
281 Ala Ala, Gly, Leu, Met, Asn, Ser, Phe 
282 Lys Lys, Ile, Met, Val, Phe, Trp 
283 Thr Thr, Ile, Leu, Val, Pro 
362 Asn Asn, Val, Met, Arg, Tyr, Phe 
365 Ser Ser, Phe, Trp 
368 Asp Pro, Ala, Met, Ser, His 
371 Ile Ile, Tyr, His, Thr 
426 Met Met, Leu, Met, Ala, Gly,  
427 Trp Trp, His, Thr, Tyr, Phe 
430 Val Val, Pro, Ile, Asp 
455 Thr Thr, Val, Ile, Val, Ile, Phe, Tyr, Trp 
456 Arg Arg, Leu, Ile, Met, Trp, Phe, Tyr 
457 Asp Asp, Phe, Tyr, Ile, Leu, Met 
460 Lys Lys, Gln, His, Leu, Met, Trp, Tyr 
461 Asp Asp, Ala, Gly, Phe, Tyr, Trp, His, Asn 
462 Thr Thr, Arg, Lys, Trp, Ala, Gly, Leu, Met, Phe, Tyr 
463 Asn Asn, Asp, Leu, Met, Ile, Leu, Val, Gly 
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  This gp120 library was screened recombinantly expressed using standard mammalian 
systems and tested for binding affinity using ELISA assays. The expression was 
performed in GnTI- cells for reduction of complex N-glycans. Expression was done in 4mL 
cultures in 24-block format and harvested by centrifuging at 2000xg for 30min. Due to the 
large number of potential mutations at each position, the entire library was very large and 
impractical to screen completely. A subset of 69 clones was randomly chosen in the first 
round of screening. Figure 3 shows OD measurements for a subset of expressed 
constructs.  
 
Figure 3. A concentration measurement for a subset of expressed constructs.  
 
  The recent installment of a robotic system for performing large-scale expression and 
ELISA screening allowed automation in the entire procedure. ELISAs were performed on 
the panel of engineered constructs for binding to the 3BNC60 germline, and a sample 
binding curve is given in Figure 4. No significant binders were identified on this initial round 
of screening which suggested that we needed more stringent selection and design criteria 
in the computational step. 
 
Figure 4. ELISAs for testing the binding of engineered gp120s to the 3BNC60 germline. 
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Design of an NIH45-46 germline chimera activator 
NIH45-46 is another highly potent antibody against HIV and vaccine candidates that can 
induce production of similar antibodies would be a highly effective preventative medicine. 
The germline chimera is a version of the antibody in which mature light chain is paired with 
the germline heavy chain. This construct demonstrates better binding to most gp120s than 
the germline version alone, which allows us to generate a rank order of weak binders that 
otherwise would be undetectable in the complete germline background. In order to design 
a gp120 that can bind to this germline chimera, we started with a computational approach 
to approximate the positions of germline HC and LC residues in an antibody-gp120 co-
crystal structure using existing structures from hypermutated antibodies-gp120 complexes. 
These include the co-crystal structures of NCS93TH057 (gp120) in complex with NIH45-
46, VRC01, VRC03 and VRC-PVG09, the first three being highly potent broadly 
neutralizing antibodies. The method carried out in Rosetta applies a grafting technique in 
which the carboxyl-amino backbone of the protein complex is assumed to be fixed during 
residue reconstruction, and side-chain rotomers are chosen based off of the lowest energy 
conformation out of ~6000 possible conformations. Upon generating this initial structure, 
visual inspection allowed us to pinpoint regions in the structure where mutations might 
lead to a greater favorability in complex formation. These mutations were then generated 
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in silico and the new structure was scored based on a standard free energy score function. 
A new structure with the mutation was then generated and visual inspection applied to see 
if the desired effect was achieved. This process was repeated several times until a list of 
potential favorable mutants was generated. The complete list of mutations designed and 
constructed by this process is given in Table 3, along with rational for the mutation. Figure 
5 shows two examples of residue replacement from the reconstructed 45-46GL-
NCS93TH057 complex that may lead to a salt bridge formation and thus improved 
binding. 
 
Table 3. Initial list of mutations and SPR results of the first set of mutations. 
# Mutation Rational 
1 S365Q Increased salt bridge interaction with HC 65Q of 60GL 
2 S365Y Hydrophobic alternative to compare with S365Q 
3 T455Q Improved polar interactions with nearby residues 
4 T455Y Hydrophobic alternative to compare with T455Q 
5 T460Q Improved polar interactions with nearby residues 
6 T467Q Increased salt bridge interaction with HC 65Q of 60GL 
7 A460Q, T463A, S464A, 
T467Q 
Eliminate N-linked glycosylation sites at 461, 462 and 465, 
a primary interface between the gp120 and the GL 
antibody. 
8 A460Q, N462Q, T463A, 
T467Q 
Second mechanism to eliminate N-linked glycosylation 
sites at 461, 462 and 465. 
9 Delete: 462, 464; T467Q Decrease the size of the V5 loop to 7 residues. Most 
gp120s have a loop size around 5-6 aa residues, and 
shortened V5 length is associated with better binding. 
NCS93TH057 has 9 aa residues. Additionally, test T467Q 
in context of loop size reduction. 
10 Delete: 462, 464, 465 Decrease the size of the V5 loop to 6 residues. 
11 Delete: 462, 464; N279D, 
T467Q 
Out of all of the existing gp120s, N and D account for 
nearly 100% of the residue identity at 279. Defective PVL 
antibodies tend to prefer D at 279, which eliminates a 
glycosylation site and suggest that this mutation may 
provide further assistance to binding. This was 
superimposed onto the V5 loop of mutant 9 after the first 
round of binding. 
12 Delete: 462, 464; T455Q, 
T467Q 
Combining mutants 3 and 9 which initially demonstrated 
improved binding to the GL and chimera precursors. 
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  In order to determine the binding affinity of the mutants to the germline and chimeric 
versions of the precursor antibody, two binding assays were used: a gp120 ELISA and SPR. 
Both protocols are detailed in the methods section. The mutants were initially characterized 
using a gp210 ELISA due to the ease and availability of the assay. This was performed in 
Figure 6. The results were not completely decisive however due to the overall low affinity of 
the constructs, but construct 9 (mutant 9) which later demonstrated greatest affinity for the 
germline and chimera percursors, also appears to be the best mutant here in the chimera 
ELISA. Due the overall weak affinity and insensitivity of this assay, SPR was then performed 
to further characterize binding. SPR is much more sensitive to changes in binding, and the 
binding constants generated represent binding constants relative to the wildtype (also 
known in Figure 6 as T278A, the initial mutant generated from a post-doc who pursued this 
project before leaving). 
 
Figure 5. Comparison of reconstructed germline antibody binding to NCS93TH057 
with S365Q (top) and T467Q (bottom) point mutants. Left images represent the 
mutants with added Q residue boxed; right images represent NCS93TH057 with S or T 
residues boxed. HC of the reconstructed germline is in purple. NCS93TH057 and the 
mutants are in green. In all four images, HC residue of the germline 64Q may interact 
favorably with the point mutants through salt bridge formation while having little 
interaction with the native gp120. The S365Q mutation was modeled after the 
reconstruction of VRC01, with an overall energy difference of -2.02. The T467Q mutant 
was a model of the reconstruction of the germline in the NIH45-46 scaffold, and an 
energy difference of -5.64. 
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Finally, SPR was performed on these designed constructs as shown in Figure 7. Construct 
9 demonstrated the greatest promise, along with constructs 3. Combining the mutations 
from construct 9 and 3 did not yield significant improvement to the binding; however, 
construct 11, which was construct 9 but with a N276D mutation, increased binding to the 
NIH45-46 chimera by more than 10-fold. 
 
Figure 7. SPR analysis of engineered gp120 binding to NIH45-46 germline 
 
Figure 6. Binding curves of NCS93TH057 mutants using a gp120 ELISA assay. Top: 
Mutants 1-5 along with T278A control against pure germline (Left) and germline chimera 
(Right). Bottom: Mutants 6-10 against pure germline (Left) and germline chimera (Right). 
In all of the mutants along with the control, the pure GL antibody does not bind very well 
and binding coefficients appear to be below the sensitivity of this assay. In the case of 
the chimera GL, potential improvements are seen in mutants 9, 6, 8 and 4, though again 
due to the overall poor binding of the GL and GL chimera to these gp120s, it is difficult 
to tell for certain. As a result, more sensitive assays such as SPR are planned for the 
future. One potential immediate assay is to repeat the ELISAs but with a high 
concentration of GL and GL chimera antibodies applied before detection, as it appears 
that only about around 320ng of the antibody is there a significant difference observed 
between each of the mutants with respect to the control. A range from 125ng-2000ng 
might be more appropriate for this assay. Finally, depending on the result of SPR, double 
mutants may be generated, or new designs will have to be sought to achieve the ultimate 
goal of an antigen that potently binds to the germline. 
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Design of a complete vaccine 
The gp120 with the designed interface will likely be used only as the initial antigen to prime 
activation, induce clonal expansion, and direct the first rounds of somatic hypermutation of 
the 3BNC60 germline B cell receptor. This is due to the fact that broadly-neutralizing 
antibodies against HIV require drastic changes in sequence and CDR loop length, and a 
single antigen most likely cannot encode the structural features to drive all such changes. 
A complete vaccine strategy would likely require a series antigens optimized for binding to 
the intermediate states of the antibody. As discussed previously, the roadmap for how a 
PVL antibody, or any HIV antibody, evolves into its final form is only starting to be written. 
Generation of a complete vaccine strategy will likely require additional clinical data defining 
these natural pathways. Though outside the scope of this particular project, rational gp120 
design as discussed for this project will likely be an essential tool in process, providing the 
platform for constructing molecular features into an antigen in order to direct the evolution 
of a potent protective descendent.  
  We have also run a second designed and have begun screening the results with 
stringent selection criteria. The primary difference in this round of design is the relaxation 
step. Rather than performing a high resolution large-scale relaxation on the mutated 
gp120-3BNC60 germline complex, we utilized shear and small movers which screen for 
small torsion angle adjustments and accept or reject them based on the Metropolis 
criterion. This is much more suitable since we already have a good idea of how the 
structure should look from the initial alignment. The selection criterion also looks for 
complexes in which the PVL signature residues17 are key players in mediating contact with 
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the engineered gp120. The structures that emphasize binding with these residues are 
more likely to be good candidates both in terms of computational accuracy as well as a 
final candidate for a vaccine. 
  Improvements can also be made in the future for engineering gp120s. Currently, the 
design protocol allows only for mutations in the existing structure. However, given the 
variability in length of the loops in the gp120s and their drastic effects on binding (which 
we saw when we truncated the V5 loop of 93TH057), an ideal program should be able to 
generate and score insertions and deletions in the loop regions of the gp120. We’re 
currently working on a protocol that can limit these changes to the loop region, and 
effectively re-pack the side-chain rotomers.  
  If such a protocol can be generated, we may be able to further expand the script to 
simultaneously evolve both the germline antibody and the gp120 (potentially using 
experimental guidelines from [6]). Since maturation toward a potent neutralizer will likely 
take place over several cycles of B cell selection, we would like to search for shortest 
paths of this evolution by identifying potential intermediate forms of the maturing antibody, 
and then designing the ideal immunogen candidate to target each stage. The process will 
hopefully be identifiable with somatic hypermutations in that out of an ensemble of 
mutated germline antibodies, a few will be selected for further maturation with evolving 
gp120. 
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Chapter II 
 
Design and characterization of polypeptide linkers for 
extending the arm span of an IgG antibody 
 
In this study we report the design and characterization of a variety of structured linkers in 
the context of an anti-HIV antibody b12.  
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Introduction  
Fusion proteins are engineered biomolecules containing parts from two or more genes 
synthesized as a single multi-functional construct. These have been critical in many areas 
of biological research including affinity purification (Lichty et al., 2005) and protein 
stabilization for structure determination (Zou et al., 2012). Biopharmaceuticals also employ 
bi-specific reagents in which the active drug domain is fused to a carrier domain allowing for 
the drug’s proper transport (Chen et al., 2013). Such proteins have been designed to 
penetrate epithelial membranes such as the blood brain barrier, as well as to target a specific 
cell population (Pardridge, 2010). Due to the modularity of protein domains in the generation 
of functional constructs, fusion proteins will likely have increasing importance in research 
and drug design. 
  The successful construction of fusion proteins relies on the proper choice of a protein linker 
as direct fusion of two domains can lead to compromised biological activity (Bai et al., 2005, 
Zhang et al., 2009). Several studies have utilized existing databases to compile and 
characterize linkers in naturally occurring multi-domain proteins (Argos, 1990, George and 
Heringa, 2002). These sstudies have yielded amino acid sequence propensities for natural 
linkers of various sizes and lengths, as well as information on rigidity and secondary 
structure. This information has helped the design of empirical linkers that are customized 
for particular applications.  
  Empirical linkers can be classified into three groups; flexible linkers, rigid linkers and 
cleavable linkers (Chen, Zaro and Shen, 2013). Flexible linkers are generally composed of 
small, non-polar or polar residues such as Gly, Ser and Thr. The most common is the 
(Gly4Ser)n linker (Gly-Gly-Gly-Gly-Ser)n, where n indicates the number of repeats of the 
GGGGS motif. Poly-glycine linkers have also been generated, but the addition of a polar 
residue such as serine can reduce linker-protein interactions and alleviate disturbance of 
protein function. Due to their flexibility, these linkers are unstructured and thus provided 
limited domain separation in a previous study (Evers et al., 2006). As a result, more rigid 
linkers including poly-proline motifs (Schuler et al., 2005) and an all alpha-helical linker 
A(EAAAK)nA (Arai et al., 2001) have been developed.  
  We are interested in using relatively rigid protein linkers to separate anti-HIV binding 
proteins at distances that would permit bi- or multivalent binding to HIV Env glycoproteins. 
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The idea is to create reagents capable of cross-linking within a single Env trimer (intra-spike 
crosslinking). Such reagents would take advantage of avidity effects to minimize HIV’s ability 
to evade neutralizing antibodies by rapidly mutating to lower the affinity between the HIV 
epitopes and the antigen recognition fragment (Fab) of the antibody (Klein et al., 2009). 
Though the architecture of the HIV spike trimer does not permit intra-spike cross-linking by 
most natural antibodies (Klein and Bjorkman, 2010, Zhu et al., 2006), it should be possible 
to create reagents separated by linkers of the appropriate length that would permit bivalent 
binding; i.e., binding to two sites on an HIV Env trimer, by either two identical reagents or 
two different reagents. Here we report the design, construction and characterization of a 
series of structured protein linkers incorporating both rigid and flexible domains that can be 
used to achieve a variety of different desired separations. The linkers were incorporated into 
the hinge region of an intact IgG antibody and then evaluated for their relative lengths and 
rigidities by dynamic light scattering. 
 
Methods 
Plasmid construction and protein purification 
Genes encoding designed linkers were synthesized (Blue Heron) with restriction sites for 
the enzymes NheI and either NgoMIV or HindIII. These sites were also introduced into the 
gene encoding the heavy chain of the HIV-neutralizing antibody b12 (Roben et al., 1994) 
such that the insert would be located between hinge region residues His235 and Thr236. 
Linker genes were subcloned into the b12 heavy chain gene, and the genes encoding the 
b12-linker fusion proteins were subcloned into the pTT5 mammalian expression vector. b12-
linker IgGs were expressed transiently in HEK-6E cells by co-transfecting the b12-linker 
heavy chain genes with the b12 light chain gene as described (Diskin et al., 2011).  
  IgG-linker fusion constructs were purified by protein A affinity chromatography (GE 
Healthcare) followed by purification and analysis over size exclusion chromatography (SEC) 
using a Superdex 200 10/300 GL column (GE Healthcare) in phosphate-buffered saline, 
0.05% w/v sodium azide, pH 7.4.  
 
Dynamic light scattering (DLS) 
Fractions corresponding to the center of the SEC elution peak were concentrated using 
Amicon Ultra-15 Centrifugal Filter Units (Millipore) with a molecular weight cutoff of 100kDa 
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to a volume of 80-400uL and concentrations of 0.5-1mg/mL. Concentration differences 
within this range did not appear to affect the hydrodynamic radius values determined by 
DLS (data not shown). Sample sizes ranging from 80-350µL were loaded into a disposable 
cuvette, and measurements were performed on a DynaPro® NanoStarTM (Wyatt 
Technology) using manufacturer’s suggested settings. A fit of the second order 
autocorrelation function to a globular protein model was performed in order to derive the 
hydrodynamic radius. 
 
Results and Discussion 
Design and identity of designed linkers 
In order to design potential structured linkers, we surveyed the Protein Data Bank (PDB) to 
find structures that were relatively elongated and rigid, or represented small globular 
proteins, with the idea of joining these in various combinations with short flexible linkers. For 
a relatively rigid, elongated structure, we chose Zn-α2-glycoprotein (ZAG; PDB code: 1ZAG) 
(Sanchez et al., 1999), and as examples of small globular proteins, we chose β2-
microgloblin (β2m) and ubiquitin (Ub; PDB code: 1UBQ). β2m is a stable 12kDa protein with 
an immunoglobulin constant region-like fold that forms a rigid structure with a separation 
distance between the N- and C-terminus of approximately 35Å (Trinh et al., 2002). Likewise, 
Ub is a compact, stable 8.5kDa protein with an N-terminal and C-terminal separation 
distance of about 37Å (Vijay-Kumar et al., 1987). Proline-rich linkers were also generated 
using the hinge sequence from IgA1, which is a glycosylated peptide that is able to confer 
rotational flexibility on the Fab relative to the Fc in the context of wildtype dimeric 
IgA1(Bonner et al., 2008). ZAG, β2m and Ub proteins were joined in various combinations 
with short linker regions, either (Gly2Ser)n repeats or proline-rich sequences, to create 
linkers L1 – L12 (Table 1).   
  We also created linkers (L13 – L16; Table 1) using tetratricopeptide repeat domains (TPRs; 
PDB code: 2AVP) (Kajander et al., 2007) that are found in natural proteins such as 
HSP70/90 (Scheufler et al., 2000). These domains are optimal for use as potential 
structured linkers because the length of a set of tandem TPR domains corresponds 
predictably with the number of repeats. Each repeat consists of 34 amino acids with a 
defined sequence motif that forms two α-helices (D'Andrea and Regan, 2003). 7-8 TPRs 
form a complete superhelical turn with a pitch of about 72Å. For our TPR constructs, we 
 
24 
 
used a consensus sequence defined by the amino acid of the greatest global propensity in 
the natural database of the TPR domains at each position, which was shown to form a stable 
superhelix and was therefore named the consensus TPR sequence or cTPR (Main et al., 
2003).  
  For comparisons, we constructed a series of (Gly4Ser)n linkers (L17 – L24; Table 1) in 
order to determine the effect of increasing the number of flexible Gly4Ser repeats on the 
hydrodynamic radius of the IgG. Table 1 summarizes the sequence identity of our designed 
set of linkers. The complete sequence of each linker is given in Table S1. 
  As a scaffold for comparing the designed structured linkers, we inserted each into the hinge 
region of an intact IgG antibody (the anti-HIV antibody b12) (Roben et al. citation). The hinge 
region of an IgG, which encompasses the amino acids between the C-terminus of the heavy 
chain portion of the antigen-binding fragment (Fab) and the N-terminus of the Fc, can 
tolerate large protein insertions (Figure 1).  
 
Characterization of the IgGs containing structured linkers 
b12 IgG proteins containing linkers L1 – L24 were expressed by transient transfection in 
mammalian cells and purified by affinity and size exclusion chromatography. Visualization 
by SDS-PAGE for IgGs containing the L1 – L8 linkers showed that all proteins were purified 
to >95% homogeneity (Figure 2). Under reducing conditions, two heavy chain bands were 
observed for b12-L1, which included a linker containing three potential N-linked 
glycosylation sites, indicating the presence of multiple glycosylated isoforms. An overlay of 
the chromatograms derived from SEC showed that the IgGs containing the L1 – L8 
structured linkers all exhibited a decrease in retention volume relative to wild type IgG, 
consistent with the expected increases in the radius of gyration (Rg) of each of the constructs 
due to the addition of a structured linker.  
  We next derived the hydrodynamic radii using dynamic light scattering (DLS) for wildtype 
b12 and the b12 proteins containing designed linkers. DLS measures fluctuations in the 
intensity of scattered light of a protein solution over time, which can be used to calculate an 
autocorrelation function of intensity (Nobbmann et al., 2007). Typical monodisperse 
samples (including our hinge-linked antibodies) generate an exponential decay in the 
autocorrelation. A least squares fit can be performed to calculate the decay constant, which 
directly relates to the diffusion coefficient. The diffusion coefficient is then inversely related 
 
25 
 
to the characteristic hydrodynamic radius RH, which reflects the radius of a hypothetical solid 
sphere that would diffuse at the same rate as the protein. The RH value is not a direct 
measurement of the length that the linker contributes to the size of the IgG. However, 
comparative analysis can yield rank order differences for the relative lengths and rigidity of 
the various linkers. For example, if the separation between the IgG Fc and Fab domains 
were increased by the addition of a designed hinge linker, we would expect an observable 
increase in the RH of the fusion construct compared to the parental b12 IgG due to increased 
size of the diffusion sphere.   
  The b12-linker proteins were separated into three groups, and the hydrodynamic radii were 
measured for each of the IgG-linker fusion proteins and compared with an internal wildtype 
b12 IgG control. The first group consisted of L1-L12, which were designed fusion constructs 
containing elongated or small protein domains separated by internal flexible linking regions. 
The second group consisted of L13-L16, which contained linkers constructed using different 
numbers of cTPRs. The final group comprised b12 IgGs that included flexible (Gly4Ser)n 
linkers of various lengths (L16 – L24), which allowed us to directly compare the effects of 
incorporating different lengths of flexible versus structured proteins linkers. 
 Figure 4 displays hydrodynamic radius data for IgGs incorporating the designed linkers. We 
observed a consistent trend for the RH values between glycosylated and non-glycosylated 
linkers. For proline-rich linkers derived from the hinge region of IgA1, incorporation of three 
potential N-linked glycosylation sites appeared to increase the length of the linker, possibly 
through stabilization of the folded state leading the linker to adopt a more extended 
conformation (Shental-Bechor and Levy, 2008). While the addition of a single potential N-
linked glycosylation site did not seem to affect the length of proline-rich linkers, potential N-
linked glycosylation in the Gly2Ser region of a combination proline-rich and Gly2Ser linker 
(L3) increased its length beyond the length of a larger glycosylated proline-rich linker (L1). 
These observations were consistent with the observation that potential N-linked 
glycosylation confers rigidity in the backbone of a flexible linker resulting in a more extended 
conformation (Liu et al., 2000). Thus incorporating potential N-linked glycosylation sites 
within flexible linkers may be a method to increase linker rigidity. 
  A single β2m domain appeared to increase the hydrodynamic radius of the IgG more than 
the proline-rich linker derived from the hinge region of IgA1 (comparing L4 and L5). 
However, two tandem β2m domains separated by a non-glycosylated (Gly2Ser)4 peptide 
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provided only a moderate increase in the apparent size of the linker compared to a single 
β2m domain (comparing L5 and L8). This is consistent with the observation that an 
additional β2m domain, when joined with a (Gly2Ser)3GAS peptide, did not significantly 
increase the hydrodynamic radius of the hinge-linked IgG compared to the wildtype IgG 
(comparing L6 and L7). These results demonstrated that coupling a flexible GlySer linker 
with the rigid β2m domain partially abrogated the separation between Fc and Fab regions 
provided by β2m alone. A similar observation was made for hinge constructs containing 
ZAG. A linker containing ZAG alone appeared to increase the hydrodynamic radius of the 
IgG more than the proline-rich linker (comparing L10 and L4). However, replacement of a 
proline-rich domain with ZAG that is flanked at both termini by a (G2S)4 peptide resulted in 
a decrease in hydrodynamic radius (comparing L10 and L11).  
 
cTPR linker series 
cTPR constructs were generated with 3, 6, 9 and 12 tandem repeats. All cTPR linkers were 
flanked by (Gly4Ser)3 sequences. By SEC, we saw a consistent decrease in elution volume 
as a function of the repeat length (Figure 3). These constructs also predictably increased 
the RH of the linked IgG with increased number of tandem repeats (Figure 4). The 
hydrodynamic radius of the cTPR12 construct corresponded to approximately the size of 
L4, a proline-rich linker. These data indicated that the increase in separation between the 
Fab and Fc provided by the linker correlated predictably with the number of cTPRs, despite 
the presence of Gly4Ser peptides flanking the N and C-termini.  
 
(Gly4Ser)n linker series 
Unlike the SEC profiles for designed linker constructs, there were only small differences in 
elution volume for the IgGs including Gly4Ser linkers (L17 – L24). These small differences 
did not necessarily correlate with molecular mass of the linkers as GS9, the IgG with the 
largest linker, eluted at approximately the same volume as wildtype IgG, which eluted after 
some of the constructs with shorter linkers (Figure 3). 
  Unlike proline-rich linkers and rigid linkers consisting of natural protein domains such as 
β2m, Gly4Ser linkers that did not contain a potential N-linked glycosylation site did not 
detectably increase the hydrodynamic radius of the IgG, suggesting that these linkers did 
not provide increased separation between the Fab and Fc domains. An internal control of 
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(Gly4Ser)9 from two preparations showed a slight variation between the two measurements 
by about 0.1nm, a small difference compared with the others in Figure 4. These results are 
consistent with the observation that Gly4Ser linkers did not provide significant separation 
between the joined domains in the context of other fusion proteins (Arai, Ueda, Kitayama, 
Kamiya and Nagamune, 2001). 
  Proper linker choice is important for the construction of multifunctional fusion proteins, and 
linkers come in many varieties with regard to effective length and rigidity. In this study, we 
used size exclusion chromatography and dynamic light scattering to characterize the 
behavior of designed linkers in the context of an IgG in order to determine whether these 
linkers could be used to increase the distance between the antigen binding fragments. We 
found that flexible Gly4Ser linkers did not increase the RH of fused reagents, and as a result 
did not provide adequate separation between the Fab and Fc domains even with up to 9 
Gly4Ser repeats. By contrast, the structured helical cTPR linkers, even when fused to more 
flexible Gly4Ser domains, provided consistent increases in separation distances as a 
function of repeat number. Various other designed linkers including those containing 
naturally occurring proteins such as β2m and ZAG were able to increase separation 
distances, but in some cases such as the β2m and ZAG-containing linkers, fusion with a 
flexible Gly4Ser linker tended to alleviate this effect. The systematic characterization of the 
lengths and rigidity properties of the structured protein linkers and a range of (Gly4Ser)n 
linkers reported here should provide a new set of tools to the available linker repertoire.  
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Figure legends 
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Fig. 1. A. Schematic of wildtype IgG (left) and IgG including designed linkers in its hinge 
region (middle). IgG domains are shown individually on the right. B. Ribbon diagrams for 
structured domains and their relative sizes. The consensus tetratricopeptide repeat contains 
8 tandem repeats. The N- and C-terminal residues are shown as sticks, color-coded blue 
for the N-terminus and red for the C-terminus. Protein data bank codes: ZAG (1ZAG), β2m 
(1LDS), cTPR (2FO7), ubiquitin (1UBQ).   
Fig. 2. SDS-PAGE analysis of IgG-structured linker proteins run under reducing (left) or 
non-reducing (right) conditions. 
Fig. 3. Overlay of size exclusion chromatograms for IgGs containing flexible and structured 
protein linkers. Structured linkers (L1-L8) exhibited larger decreases in retention volume 
with respect to wildtype compared to Gly4Ser linkers, which exhibited little to no decrease 
depending on the number of repeats. Structured cTPR linkers also exhibited consistent 
decreases in retention volume as a function of the number of repeats.  
Fig. 4. Comparative analysis by DLS of the hydrodynamic radii (RH) of designed linkers in 
the context of the b12 IgG. 
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 (Table 1) 
Table 1. Description of structured linker designs. 
(Gly4Ser)n=Gly-Gly-Gly-Gly-Ser sequence with n number of 
repeats; GlySer = (N-term: AGS(GGS)3; Middle: (GGS)4; C-
term: (GGS)3GAS]2S); GlySer(Glyc)=Gly-Gly-Ser sequence 
with an embedded potential N-linked glycosylation site (Asn-
Ser-Ser); polyPro=proline-rich hinge sequence from IgA1; 
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polyPro(Glyc)=proline-rich hinge sequence from IgA1 with an 
embedded potential N-linked glycosylation site (Asn-Ser-
Ser); β2m=β-2-microglobulin; Ub=ubiquitin; ZAG=Zn-α2-
glycoprotein; cTPRX=consensus tetratricopeptide repeat 
sequence with X number of repeats. 
Linker Name Description 
L1 GPcPcPc GlySer-polyPro(Glyc)-polyPro(Glyc)-polyPro(Glyc) 
L2 GPPcP GlySer-polyPro-polyPro(Glyc)-polyPro 
L3 GPGcP GlySer-polyPro-GlySer(Glyc)-polyPro 
L4 GPPP GlySer-polyPro-polyPro-polyPro 
L5 GPbP GlySer-polyPro-β2m-polyPro 
L6 GPbG GlySer-polyPro-β2m-GlySer 
L7 PbGbG polyPro-β2m-GlySer-β2m-GlySer 
L8 GPbGbP GlySer-polyPro-β2m-GlySer-β2m-polyPro 
L9 GPUG GlySer-polyPro-Ub-GlySer 
L10 GPZP GlySer-polyPro-ZAG-polyPro 
L11 GGZGZP GlySer-GlySer-ZAG-GlySer-ZAG-polyPro 
L12 GcGcP GlySer(Glyc)- GlySer(Glyc)-polyPro 
L13 cTPR3 (G4S)3-cTPR3-(G4S)3 
L14 cTPR6 (G4S)3-cTPR6-(G4S)3 
L15 cTPR9 (G4S)3-cTPR9-(G4S)3 
L16 cTPR12 (G4S)3-cTPR12-(G4S)3 
L17 GS1 (G4S)1 
L18 GS2 (G4S)2 
L19 GS3 (G4S)3 
L20 GS5 (G4S)5 
L21 GS6 (G4S)6 
L22 GS7 (G4S)7 
L23 GS8 (G4S)8 
L24 GS9 (G4S)9 
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(Table 2) 
Table 2. Complete sequences of designed linkers. Linkers 
L1-L21 were inserted into the hinge region of b12 IgG 
between residues His235 and Thr236. Linkers L22-L24 were 
inserted into the same hinge between residues Cys231 and 
Asp232. 
Linker Name Complete Sequence 
L1 GPcPcPc AGSGGSGGSGGSPVPSTPPTNSSSTPPTPSPSPVPSTPPTNSSSTPPTPSPSPVPSTPPTNSSSTPPTPSPSAS 
L2 GPPcP AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSPVPSTPPTNSSSTPPTPSPSPVPSTPPTPSPSTPPTPSPSAS 
L3 GPGcP AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSGGSGNSSGSGGSPVPSTPPTPSPSTPPTPSPSAS 
L4 GPPP AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSPVPSTPPTPSPSTPPTPSPSPVPSTPPTPSPSTPPTPSPSAS 
L5 GPbP 
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYS
RHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDL
SFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDR
DPVPSTPPTPSPSTPPTPSPSAS 
L6 GPbG 
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYS
RHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDL
SFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDR
DGGSGGSGGSGGSAS 
L7 PbGbG 
AGPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYSRHPAENGKSN
FLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYL
LYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDGGSGGSGG
SGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDL
LKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRV
NHVTLSQPKIVKWDRDGGSGGSGGSGAS 
L8 GPbGbP 
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYS
RHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDL
SFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDR
DGGSGGSGGSGGSIQRTPKIQVYSRHPAENGKSNFLNCYVS
GFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTP
TEKDEYACRVNHVTLSQPKIVKWDRDPVPSTPPTPSPSTPPTP
SPSAS 
L9 GPUG 
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSQIFVKTLTGK
TITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTL
SDYNIQKESTLHLVLRLRGGGGSGGSGGSGGSAS 
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L10 GPZP 
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSDGRYSLTYIY
TGLSKHVEDVPAFQALGSLNDLQFFRYNSKDRKSQPMGLWR
QVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVL
QGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDP
AAQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILD
RQDPPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAGE
VQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHS
SLAQPLVVPWEASPVPSTPPTPSPSTPPTPSAS 
L11 GGZGZP 
AGSGGSGGSGGSGGSGGSGGSGGSDGRYSLTYIYTGLSKHV
EDVPAFQALGSLNDLQFFRYNSKDRKSQPMGLWRQVEGMED
WKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGCE
IENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQK
WEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVV
VTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRG
DVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVV
PWEASGGSGGSGGSGGSDGRYSLTYIYTGLSKHVEDVPAFQ
ALGSLNDLQFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQ
LQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGCEIENNRSS
GAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAEPV
YVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQA
PGEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNG
NGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPWEASP
VPSTPPTPSPSTPPTPSPSAS 
L12 GcGcP AGSGNSSGSGGSGGSGNSSGSGGSPVPSTPPTPSPSTPPTPSPSAS 
L13 cTPR3 
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIE
YYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEYYQKALEL
DPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNNLQR
SAGGGGSGGGGSGGGGAS 
L14 cTPR6 
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIE
YYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEYYQKALEL
DPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNNLQAE
AWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNLGN
AYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGD
YQKAIEDYQKALELDPNNRSRSAGGGGSGGGGSGGGGAS 
L15 cTPR9 
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIE
YYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEYYQKALEL
DPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNNLQAE
AWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNLGN
AYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGD
YQKAIEDYQKALELDPNNRSAEAWYNLGNAYYKQGDYQKAIE
YYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEYYQKALEL
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DPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNNLQR
SAGGGGSGGGGSGGGGAS 
L16 cTPR12 
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIE
YYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEYYQKALEL
DPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNNLQAE
AWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNLGN
AYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGD
YQKAIEDYQKALELDPNNRSAEAWYNLGNAYYKQGDYQKAIE
YYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEYYQKALEL
DPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNNLQAE
AWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNLGN
AYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGD
YQKAIEDYQKALELDPNNRSAGGGGSGGGGSGGGGAS 
L17 GS1 GGGGSAS 
L18 GS2 GGGGSGGGGSAS 
L19 GS3 GGGGSGGGGSGGGGSAS 
L20 GS5 GGGGSGGGGSGGGGSGGGGSGGGGSAS 
L21 GS6 GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS 
L22 GS7 AGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS 
L23 GS8 AGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS 
L24 GS9 AGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS 
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